From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non–Small Cell Lung Cancer
A Fukuda, Y Okuma - Clinical Cancer Research, 2024 - AACR
In the realm of advanced non–small cell lung cancer (NSCLC) harboring epidermal growth
factor receptor (EGFR) therapy with tyrosine kinase inhibitors (TKI), addressing optimal …
factor receptor (EGFR) therapy with tyrosine kinase inhibitors (TKI), addressing optimal …
Investigation of age and smoking in NSCLC patients with uncommon EGFR mutations.
Y Maezawa, M Taguchi, T Kawakami, T Inui… - Tuberkuloz ve …, 2024 - europepmc.org
Materials and methods We retrospectively reviewed the medical records of non-small cell
lung cancer (NSCLC) patients diagnosed in a multicenter clinical practice from 2002 to …
lung cancer (NSCLC) patients diagnosed in a multicenter clinical practice from 2002 to …
Genetic differences between smokers and never-smokers with lung cancer
P Kusnierczyk - 2023 - europepmc.org
Smoking is a major risk factor for lung cancer, therefore lung cancer epidemiological trends
reflect the past trends of cigarette smoking to a great extent. The geographic patterns in …
reflect the past trends of cigarette smoking to a great extent. The geographic patterns in …
Will CHRYSALIS turn into a butterfly?
T Fuereder - ESMO open, 2022 - esmoopen.com
On 9 December 2021, the European Commission granted conditional marketing approval
(CMA) of amivantamab for the treatment of adult patients with advanced non-smallcell lung …
(CMA) of amivantamab for the treatment of adult patients with advanced non-smallcell lung …
Alteraciones genómicas concurrentes en pacientes con cáncer de pulmón de células no pequeñas con mutación de EGFR
RA Reyna de la Garza - 2023 - eprints.uanl.mx
El cáncer de pulmón es la primera causa de muerte por cáncer a nivel mundial y la segunda
neoplasia más diagnosticada. El cáncer de pulmón de células no pequeñas (CPCNP) es el …
neoplasia más diagnosticada. El cáncer de pulmón de células no pequeñas (CPCNP) es el …
[PDF][PDF] Plicní adenokarcinom se vzácnou EGFR mutací i nečastou rezistencí k léčbě.
M Svatoň, T Vaněček, P Mukenšnabl… - Studia Pneumologica …, 2022 - plicnilekarstvi.cz
Tyrosine kinase inhibitor (TKI) therapy is a standard of care in patients with frequent
mutations in the epidermal growth factor receptor (EGFR) gene, ie L858R point mutation and …
mutations in the epidermal growth factor receptor (EGFR) gene, ie L858R point mutation and …
Successful Therapy of A Critically Ill Nsclc Patient With Uncommon Mutations in Egfr G719x and S768i Genes Using Furmonertinib: A Case Report
X Pan, M Shi - Available at SSRN 4672163 - papers.ssrn.com
Background: Somatic mutations in the genes of epidermal growth factor receptors (EGFR)
such as G719X and S768I and tyrosine kinase inhibitors (TKIs) are strongly confirmed to be …
such as G719X and S768I and tyrosine kinase inhibitors (TKIs) are strongly confirmed to be …
[引用][C] Prävalenz von EGFR-Mutationen bei nicht-kleinzelligen Lungenkarzinomen in Österreich
PDDS Watzka, BM George